Investor Relations

1st QUARTER 2023


Evonik has published its quarterly report Q1 2023 on May 9, 2023. 

You can access further information here.

  • Q1 adj. EBITDA of only €409 m due to low volumes and despite positive pricing in Specialties; PA12 ramp-up driving Smart Materials, slow start in Specialty Additives, price pressure in Animal Nutrition
    and C4
  • Through Q1 every month with sequentially better earnings – Start into Q2 continues on improved
    March level
  • First divestment in Performance Materials: Divestment of Lülsdorf site signed; alkoxides business integrated into Smart Materials
  • Strengthening competitiveness of Animal Nutrition business: Two separate operating models, with focus on efficiency and cost-leadership in amino acids
  • Outlook FY 2023 confirmed: Lower end of adj. EBITDA range (€2.1 – 2.4 bn) more likely

Reporting 1st Quarter 2023

Link / PDF
Analyst & Investor Factsheet
Presentation Conference Call

Detailed overview of key financial data (Evonik Financials) - as PDF

Detailed overview of key financial data (Evonik Financials) - as Excel

Quarterly Statement Q1 2023

Investor Relations News Q1 2023

Analysts' consensus* (Vara Research)

Webcast Conference Call Q1 2023
(May 9, 2023, 11.00 am CEST)

* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.